With 1.4 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.52 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $6.0 whereas the lowest price it dropped to was $4.84. The 52-week range on HCWB shows that it touched its highest point at $100.80 and its lowest point at $2.77 during that stretch. It currently has a 1-year price target of $35.00. Beta for the stock currently stands at 0.69.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of HCWB was up-trending over the past week, with a rise of 65.45%, but this was up by 41.93% over a month. Three-month performance dropped to -26.38% while six-month performance fell -58.98%. The stock lost -66.99% in the past year, while it has lost -65.02% so far this year. A look at the trailing 12-month EPS for HCWB yields -16.07 with Next year EPS estimates of -5.01. For the next quarter, that number is -2.30. This implies an EPS growth rate of 85.06% for this year and -8.91% for next year. EPS is expected to grow by 55.47% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -29.55%.
Float and Shares Shorts:
At present, 2.15 million HCWB shares are outstanding with a float of 1.63 million shares on hand for trading. On 2025-08-15, short shares totaled 38223.0, which was 178.0 higher than short shares on 1752537600. In addition to Dr. Hing C. Wong Ph.D. as the firm’s Founder, CEO, Director & Secretary, Dr. Peter Rhode Ph.D. serves as its Chief Scientific Officer & VP of Clinical Operations.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, HCWB reported revenue of $6550.0 and operating income of $-3361829.0. The EBITDA in the recently reported quarter was $-3053540.0 and diluted EPS was $-0.898038.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With HCWB analysts setting a high price target of 35.0 and a low target of 35.0, the average target price over the next 12 months is 35.0. Based on these targets, HCWB could surge 494.23% to reach the target high and rise by 494.23% to reach the target low. Reaching the average price target will result in a growth of 494.23% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $-22.8 being high and $-22.8 being low. For HCWB, this leads to a yearly average estimate of $-22.8. Based on analyst estimates, the high estimate for the next quarter is $-2.43 and the low estimate is $-2.43. The average estimate for the next quarter is thus $-2.43.
